Voyager Therapeutics Inc (VYGR) — Cash Flow Quality Index
Voyager Therapeutics Inc (VYGR) has a Cash Flow Quality Index of -0.42x as of December 2023. Operating cash flow of $-23.76 Million is below net income of $56.40 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore VYGR cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Voyager Therapeutics Inc Cash Flow Quality Index (2020–2023)
Historical Cash Flow Quality Index for Voyager Therapeutics Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Voyager Therapeutics Inc cash conversion from operations.
Annual Cash Flow Quality Index for Voyager Therapeutics Inc (2020–2023)
Year-by-year earnings quality comparison for Voyager Therapeutics Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | 0.59x | $77.92 Million | $132.33 Million | ▲ +122.4% |
| 2020 | -2.63x | $-96.72 Million | $36.74 Million | — |